New report issued by Milken Institute and Wellcome Trust on financing antibiotic development
FasterCures and Financial Innovations Labs® have joint forces on a project to identify new financing models to revive the R&D pipeline for new antibiotics against antimicrobial resistant bacteria. The Milken Institute, in partnership with Wellcome Trust, hosted a Financial Innovations Lab to examine existing and new solutions. The results were published in the Milken Institute’s recent report.
COVID-19 has shown how consequential public health risks are to the economy. As investors broadly increase their focus in this field, antimicrobial resistance (AMR) is likely to be of growing concern. If left unchecked, AMR may cost the global economy as much as $100 trillion by 2050. Understanding the growing prevalence of AMR infections, health organizations have declared AMR one of today’s most significant threats to global health. Together with Wellcome Trust, Milken Institute hosted a Financial Innovations Lab to investigate the already existing and solutions and to help find new ones to revitalize the pipeline of antibiotics. Here, participants discussed possible funding and financing mechanisms to spur the research and development of antibiotics and reward the successful development of novel antimicrobials. Discussions included exploring the option of a social impact bond to pay for antibiotic development similar to traditional infrastructure. Making use of the Milken Institute’s network, participants investigated the feasibility of a blended capital vehicle, as well as debt options, taking into account return expectations at different stages of the R&D pipeline.
Read the executive summary: https://milkeninstitute.org/sites/default/files/2022-03/FIL-AMR%20Executive%20Summary%20v3.21.22%20%281%29.pdf
Download the report pdf: https://milkeninstitute.org/sites/default/files/2022-03/FIL-AMR%20v3.22.22.pdf